Cancer Patents (Class 436/64)
  • Patent number: 10126311
    Abstract: Some embodiments of the present invention relate to methods and compositions for assessing the absence, presence, progression, or stage of cancer. In particular, methods and compositions for detecting endometrial cancer or ovarian cancer are provided.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: November 13, 2018
    Assignee: UNIVERSITY OF SOUTH ALABAMA
    Inventors: Michael A. Finan, Rodney P. Rocconi, Lewis K. Pannell
  • Patent number: 9624547
    Abstract: Presented herein are biomarkers related to breast cancer. The presently identified salivary biomarkers create the basis for a breast cancer detection bioassay with sensitivity and specificity. Means and methods for evaluating the data generated using multiple biomarkers in order to validate findings and further use of the multiplexed breast cancer assay in clinical, diagnostic and therapeutic uses is also included.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: April 18, 2017
    Assignee: The Regents of the University of California
    Inventors: David T. Wong, Lei Zhang, Hua Xiao, Hui Zhou
  • Patent number: 9528159
    Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterizing the proliferation properties of the respective cell. The characterization of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: December 27, 2016
    Assignee: VENTANA MEDICAL SYSTEMS, INC.
    Inventors: Ruediger Ridder, Anja Reichert, Marcus Trunk, Richard Batrla
  • Patent number: 9459267
    Abstract: Provided are methods for determining the amount of tamoxifen and its metabolites in a sample by mass spectrometry. In some aspects, the methods provided herein determine the amount of norendoxifen. In some aspects, the methods provided herein determine the amount of norendoxifen and tamoxifen. In some aspects, the methods provided herein determine the amount of norendoxifen and other tamoxifen metabolites. In some aspects, the methods provided herein determine the amount of tamoxifen, norendoxifen, and other tamoxifen metabolites.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: October 4, 2016
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Nigel Clarke
  • Patent number: 9304135
    Abstract: The present disclosure relates to stomach cancer diagnosis using tryptophan metabolism rate in one aspect, and it relates to an invention using change of tryptophan metabolism rate in a stomach cancer patient, which is different from a normal person.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: April 5, 2016
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Byung Hwa Jung, Soo Hyun Lee, Myung Soo Kim
  • Patent number: 9182403
    Abstract: Provided are methods and kits for staining cervical cell sample by contacting the cervical cell sample with a Ficus elastics plant extract, staining the cervical cell sample with New Fuchsin, and staining the cervical cell sample with Light Green or Fast Green. Also provided are method of diagnosing a pre-malignant or a malignant cervical tumor in a subject, by staining the cervical cell sample and identifying at least one cervical cell having a red cytoplasm above a pre-determined threshold, wherein presence of the at least one cervical cell having the red cytoplasm above the pre-determined threshold is indicative of a non- or less-differentiated cell as compared to a normal cervical cell, thereby diagnosing the pre-malignant or a malignant cervical tumor in the subject.
    Type: Grant
    Filed: May 17, 2010
    Date of Patent: November 10, 2015
    Assignee: Zetiq Technologies LTD.
    Inventors: Pavel Idelevich, Adi Elkeles, Dov Terkieltaub, Ami Eyal
  • Patent number: 9164098
    Abstract: A method for determining an expression of human epidermal growth factor receptor 2 (HER2) of a subject. The method includes providing a sample from the subject; measuring one of (i) amounts of two or more proteins in the sample, each protein having a molecular weight substantially equal to 4740, 8404, 8419, 8435, 8450, 8455, 8465, 8570, 8607 or 8626 atomic mass units, and (ii) amounts of at least one of human cystein-rich intestinal protein 1 (CRIP1), one or more variants of the human cystein-rich intestinal protein 1 (CRIP1 variants), and proteolytic digestion products thereof in the sample; and comparing the amounts of the proteins to control amounts, which control amounts are determinative of the expression of the human epidermal growth factor receptor 2.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: October 20, 2015
    Assignee: Bruker Daltonik GmbH
    Inventors: Christian Albers, Eckhard Belau, Sören-Oliver Deininger, Sandra Rauser, Detlev Suckau, Axel Walch
  • Patent number: 9017957
    Abstract: An object of the present invention is to provide an antibody that can be stably supplied and can react with prostasin under non-denaturation and denaturation conditions, and an antigen peptide for preparation of the antibody. The present invention relates to a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a peptide consisting of an amino acid sequence that has a deletion, a substitution, or an addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1 and having antigenicity of prostasin. Furthermore, the present invention relates to an antibody prepared using the peptide as an antigen.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: April 28, 2015
    Assignees: Hitachi Chemical Company, Ltd., Kimio Tomita, Kenichiro Kitamura
    Inventors: Hiromi Iijima, Noriya Ohta, Kimio Tomita, Kenichiro Kitamura
  • Patent number: 9012215
    Abstract: Using the methods of the present invention, intermediate (int) levels of aldehyde dehydrogenase (ALDH) activity reliably distinguished leukemic CD34+CD38? cells capable of engrafting immunodeficient mice, from residual normal hematopoietic stem cells that exhibited relatively higher ALDH activity. Minimal residual disease (MRD) detected during complete remission was enriched for the CD34+CD38?ALDHint leukemic cells, and the presence of these cells after therapy highly correlated with subsequent clinical relapse. The methods of the present invention can distinguish normal from leukemic CD34+CD38? cells, and identifies those AML cells associated with relapse. Methods of prediction of relapse of AML patients and methods of treatment are also provided.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: April 21, 2015
    Assignee: The Johns Hopkins University
    Inventors: Jonathan Michael Gerber, Richard John Jones
  • Patent number: 9005994
    Abstract: The present application pertains to improved methods of detecting biomolecules in a biological sample (or system), In particular, embodiments discussed herein allow for the detection of biomolecule complexes. The embodiments enable for the first time the elucidation of the significance of biomolecule complexes for certain disease states, which in turn enables the diagnosis of disease states based on the identity and complexing level of a biomolecule complex in a particular biological sample.
    Type: Grant
    Filed: January 12, 2011
    Date of Patent: April 14, 2015
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventor: Qun Huo
  • Patent number: 9005900
    Abstract: Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: April 14, 2015
    Assignee: Clarient Diagnostic Services, Inc.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz, Rodney A. Beck
  • Patent number: 8993333
    Abstract: Disclosed is a method of providing a risk evaluation and diagnosis of human cancer, by examining the presence, in the volatile fraction of a human saliva sample, of a combination of particulate biochemical volatile organic compounds, which is indicative of an increased risk of developing cancer.
    Type: Grant
    Filed: August 3, 2010
    Date of Patent: March 31, 2015
    Assignee: Institut Clinident
    Inventor: Franck Chaubron
  • Patent number: 8986629
    Abstract: A device for controlling, detecting, and measuring a molecular complex is disclosed. The device comprises a common electrode. The device further comprises a plurality of measurement cells. Each measurement cell includes a cell electrode and an integrator electronically coupled to the cell electrode. The integrator measures the current flowing between the common electrode and the cell electrode. The device further comprises a plurality of analog-to-digital converters, wherein an integrator from the plurality of measurement cells is electrically coupled to one analog-to-digital converter of the plurality of analog-to-digital converters.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: March 24, 2015
    Assignee: Genia Technologies, Inc.
    Inventors: Kevin Deierling, Roger J. A. Chen, David J. Fullagar
  • Patent number: 8987004
    Abstract: The present invention relates to affinity biosensing using polarization of light scattering of aggregated noble metallic nanostructures to determine concentration of an analyte in a test sample. This new sensing system utilizes the changes in polarized plasmonic scattering from nanostructures as the nanostructures aggregate due to binding of the analyte to a binding partner attached to the surface of the metallic nanostructure.
    Type: Grant
    Filed: August 2, 2006
    Date of Patent: March 24, 2015
    Assignee: University of Maryland, Baltimore County
    Inventor: Chris D. Geddes
  • Patent number: 8980638
    Abstract: Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: March 17, 2015
    Assignee: University of Massachusetts
    Inventor: Zhong Jiang
  • Patent number: 8980637
    Abstract: A method for the parallel identification of one or more metabolite species within a biological sample is provided. The method comprises producing a first spectrum by subjecting the sample to a nuclear magnetic resonance analysis, the first spectrum containing individual spectral peaks representative of the one or more metabolite species contained within the sample; producing a second spectrum by subjecting the sample to a mass spectrometry analysis, the spectrum containing individual spectral peaks representative of the one or more metabolite species contained within the sample; subjecting each of the individual spectral peaks to a statistical pattern recognition analysis to identify the one or more metabolite species contained within the sample; and identifying the one or more metabolite species contained within the sample by analyzing the individual spectral peaks of the mass and nuclear magnetic resonance spectra.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: March 17, 2015
    Assignee: Purdue Research Foundation
    Inventors: Daniel M. Raftery, Zhengzheng Pan, Haiwei Gu
  • Patent number: 8975036
    Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterizing the proliferation properties of the respective cell. The characterization of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: March 10, 2015
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Ruediger Ridder, Anja Reichert, Marcus Trunk-Gehmacher, Richard Batrla
  • Patent number: 8975030
    Abstract: The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence, status or metastasis of cancer by detecting plasma Hsp90? having the amino acid sequence of SEQ ID NO:1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: March 10, 2015
    Assignees: Tsinghua University, Protgen Ltd.
    Inventors: Yongzhang Luo, Xiaomin Song, Xiaofeng Wang, Wei Zhuo, Guodong Chang, Yan Fu
  • Publication number: 20150064796
    Abstract: A non-invasive method of detecting or screening for lung cancer in a subject specimen is provided. The method includes detecting elevated levels of one or more carbonyl-containing volatile organic compounds (VOCs) that are biomarkers for lung cancer in exhaled breath from the subject specimen. The method may further include obtaining exhaled breath from the subject specimen; forming adducts of the carbonyl-containing VOCs with a reactive chemical compound; quantifying the adducts of the carbonyl-containing VOCs to establish a subject value for each of the adducts; and comparing each subject value to a threshold healthy specimen value for each of the adducts of the carbonyl-containing VOCs. One or more subject values at quantities greater than threshold healthy specimen values are also useful for screening for lung cancer in the subject specimen.
    Type: Application
    Filed: August 28, 2014
    Publication date: March 5, 2015
    Inventors: Xiaoan Fu, Michael Nantz, Michael Bousamra
  • Publication number: 20150065373
    Abstract: A novel method that enables prostate cancer testing that is noninvasive and more accurate than conventional methods is disclosed. The present inventors intensively analyzed urine samples from prostate cancer patients, and non-cancer subjects, who are free of prostate cancer, and, as a result, newly discovered urinary peptides that can be used as indicators in prostate cancer testing. Use of these urinary peptides as indicators enables various prostate cancer-related tests including detection of prostate cancer, discrimination between prostate cancer and benign prostatic hyperplasia, monitoring of a therapeutic effect of prostate cancer therapy and monitoring of postoperative recurrence.
    Type: Application
    Filed: March 28, 2013
    Publication date: March 5, 2015
    Applicant: KYOTO UNIVERSITY
    Inventors: Kenji Nakayama, Kazuharu Shimizu, Jun Utsumi, Takahiro Inoue, Osamu Ogawa
  • Patent number: 8969046
    Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, S0X17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.
    Type: Grant
    Filed: January 9, 2008
    Date of Patent: March 3, 2015
    Assignee: MDxHealth SA
    Inventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaëtan Otto, Maarten Penning
  • Patent number: 8969100
    Abstract: Regions where metastatic cancer cells can exist are detected with high accuracy in a sentinel lymph node. Quantum dots are injected into the vicinity of a cancer in a living body, thereby identifying the location of the sentinel lymph node by means of fluorescence. Subsequently, the sentinel lymph node is extracted. With respect to the sentinel lymph node extracted with quantum dots injected, structural analysis is conducted by means of precision fluorescence measurement which uses a confocal fluorescence microscope for monomolecular observation. Specifically, the fluorescence intensity is measured with respect to each of multiple areas in the sentinel lymph nodes, and out of the multiple areas measured, one or more areas are detected as afferent lymph vessel inflow regions in descending order of fluorescence intensity.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: March 3, 2015
    Assignees: Tohoku University, Konica Minolta Medical & Graphic, Inc.
    Inventors: Makoto Hikage, Kohsuke Gonda, Motohiro Takeda, Takashi Kamei, Noriaki Ohuchi, Hideki Gouda, Yasushi Nakano
  • Publication number: 20150056605
    Abstract: The present disclosure relates to a panel of a plurality of metabolite species that is useful for the identification or detection of subjects having pancreatic cancer, including methods for identifying such metabolic biomarkers within biological samples. The disclosure also includes a statistical model for predicting the presence of pancreatic cancer in a subject's biofluid by quantifying and comparing positive and negative fold changes in metabolite species' concentration; comparing the subject's metabolite species' concentrations to a predetermined value.
    Type: Application
    Filed: August 21, 2014
    Publication date: February 26, 2015
    Applicant: PURDUE RESEARCH FOUNDATION
    Inventors: M. Daniel Raftery, Vincent M. Asiago, Kwadwo Owusu-sarfo, Bowei Xi
  • Patent number: 8962268
    Abstract: The present invention relates to a method for determining the survival prognosis of patients suffering from non-small cell lung cancer. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels in response to a kinase inhibitor and profiles in samples obtained from patients diagnosed with non-small cell lung cancer. The present invention also provides methods for predicting the response of a patient diagnosed with non-small cell lung cancer to a medicament.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: February 24, 2015
    Assignee: Pamgene B.V.
    Inventors: Richard De Wijn, Robby Ruijtenbeek, Maria Helena Hilhorst
  • Patent number: 8962267
    Abstract: The present invention relates to a method for determining or predicting the response of a patient diagnosed with non small cell lung cancer to targeted pharmacotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with non small cell lung cancer to specific medicaments. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles and inhibitions thereof by drugs in samples of said patients.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: February 24, 2015
    Assignees: Pamgene B.V., Stichting Het Nederlands Kanker Instituut
    Inventors: Richard De Wijn, Robby Ruijtenbeek, Maria Helena Hilhorst, Michael Maria Van Den Heuvel, Houke Marian Klomp
  • Patent number: 8962263
    Abstract: The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: February 24, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Omar D. Perez, Garry P. Nolan
  • Publication number: 20150044703
    Abstract: Some embodiments of the present invention relate to methods and compositions for detecting the presence of cancer. In particular, methods and compositions for detecting endometrial cancer or ovarian cancer are provided.
    Type: Application
    Filed: March 12, 2013
    Publication date: February 12, 2015
    Applicant: University of South Alabama
    Inventors: Michael A. Finan, Rodney P. Rocconi, Lewis K. Pannel
  • Patent number: 8951744
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: February 10, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • Patent number: 8951746
    Abstract: The present invention provides multi-parameter analysis methods for determining the presence or absence of pre-cancerous or cancerous cells in a cervical sample and for screening cervical abnormality in a cervical sample. The invention also provides an apparatus and automated methods for screening cervical abnormality in a sample. The invention further provides a sampling device and a sample collection assembly for collecting cell samples, including cervical samples.
    Type: Grant
    Filed: November 4, 2005
    Date of Patent: February 10, 2015
    Assignee: Southwest Research Institute
    Inventors: Urs G. Wiederkehr, Jian Ling
  • Publication number: 20150037824
    Abstract: A urinary biomarker for urinary tract cancers and applications of the same are revealed. TACSTD2 is used as a non-invasive urinary biomarker for urinary tract cancers due to a feature that the TACSTD2 protein is increased significantly in urine of patients with urinary tract cancers. The quantitative urinary biomarker shows high specificity and high sensitivity for urinary tract cancer detection. Besides increasing screening efficiency, early diagnosis and early treatment of urinary tract cancers, the biomarker can also be used to assess malignancy of urinary tract cancers and monitor tumor progression for determining optimal treatment against the disease and improving the treatment results.
    Type: Application
    Filed: October 18, 2013
    Publication date: February 5, 2015
    Applicant: CHANG GUNG UNIVERSITY
    Inventors: YI-TING CHEN, JAU-SONG YU, CHIEN-LUN CHEN, YU-SUN CHANG
  • Patent number: 8946169
    Abstract: The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: February 3, 2015
    Assignee: NantBioScience, Inc.
    Inventors: Vuong Trieu, Neil P. Desai, Patrick Soon-Shiong
  • Patent number: 8945929
    Abstract: Provided are a marker for determining sensitivity to an anticancer agent capable of distinguishing a therapeutic response of an individual patient and a novel means for a cancer therapy using the marker. The marker for determining sensitivity to an anticancer agent contains a substance in a metabolic pathway in which L-phenylalanine and/or N,N-dimethyl glycine are/is involved.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: February 3, 2015
    Assignees: Keio University, Kabushiki Kaisha Yakult Honsha
    Inventors: Yusuke Tanigawara, Mitsuhiro Watanabe, Eri Arita, Akito Nishimuta, Yasuko Yamayoshi, Takeshi Matsuzaki, Shinji Sugimoto
  • Publication number: 20150031013
    Abstract: It is to provide a tumor diagnostic agent and a tumor determination method enabling not only determination of the presence or absence of a tumor in a subject, but also determination of whether the tumor is a malignant tumor or a benign tumor, which can be used simply at low cost with reduced side effects and burden. 5-aminolevulinic acid (ALA) or its derivative, or a salt thereof is orally administered at a dose of 5 to 7 mg in terms of ALA per kg of body weight, and a urine sample 4 to 12 hours after the administration is collected. Porphyrins and creatinine in the urine sample are quantitated, and based on the value (nmol/gCre) obtained by dividing the amount of porphyrins by the amount of creatinine, a distinction among an individual without a tumor, an individual with a benign tumor, and an individual with a malignant tumor is determined. The presence or absence of a malignant tumor in a subject can be clearly determined by administering 1 to 3 mg of ALAs in terms of ALA per kg of body weight.
    Type: Application
    Filed: January 15, 2013
    Publication date: January 29, 2015
    Inventors: Tohru Tanaka, Kiwamu Takahashi, Motowo Nakajima, Fuminori Abe, Masahiro Ishizuka, Urara Ota
  • Patent number: 8940493
    Abstract: Methods for the detection, enumeration and analysis of circulating tumor cells expressing insulin-like growth factor-1 receptors (IGF-1R) are disclosed. These methods are useful for cancer screening and staging, development of treatment regimens, and for monitoring for treatment responses, cancer recurrence or the like. Test kits that facilitate the detection, enumeration and analysis of such circulating tumor cells are also provided.
    Type: Grant
    Filed: May 29, 2007
    Date of Patent: January 27, 2015
    Assignees: Veridex LLC, Pfizer Inc.
    Inventors: Antonio Gualberto, Maria Luisa Paccagnella, Carrie L. Melvin, Madeline I. Repollet, David Chianese, Mark Carle Connelly, Leonardus Wendelinus Mathias Marie Terstappen
  • Patent number: 8936914
    Abstract: The present invention provides methods of aiding in a renal cell carcinoma prognosis that include quantifying expressed carbonic anhydrase in samples derived from renal cell carcinoma patients. The methods also identify patients that are likely to respond positively to selected courses of treatment. The invention further provides related computer program products.
    Type: Grant
    Filed: April 15, 2003
    Date of Patent: January 20, 2015
    Assignee: The Regents of the University of California
    Inventors: Matthew H. T. Bui, David Seligson, Arie S. Belldegrun
  • Patent number: 8923598
    Abstract: The subject invention concerns methods for the detection, diagnosis, and/or prognosis of cancer by analyzing centrosomal features. In one embodiment, a method includes receiving an image of one or more cells; selecting a region of interest in one cell; segmenting the region of interest to delineate at least one centrosomal; extracting one or more features from the segmented image; and analyzing the extracted features to diagnose cancer. In another embodiment, the progression of cancer can be predicted through analysis and classification of the extracted features. In one embodiment, the method can be performed by a quantitative cancer analysis system including a diagnosis module and/or a prognosis module. In one embodiment, the method can be performed using an image processing system.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 30, 2014
    Assignee: H. Lee Moffitt Cancer Center and Research Institute
    Inventors: Tatyana A. Zhukov, Dansheng Song, Melvyn S. Tockman
  • Patent number: 8921114
    Abstract: A diagnosis support system for cancer is disclosed that comprises: a measurement value acquiring section for acquiring a measurement value of a first cancer patient; a sample data memory for storing sample data of a plurality of cancer patients different from the first patient; a reference range determination section for determining a reference range based on the measurement value of the first cancer patient; a display unit; and a display controller for controlling the display unit to display a diagnosis support screen showing the clinical information included in the sample data having measurement value within the reference range. A method of providing cancer diagnosis support information and a computer program product are also disclosed.
    Type: Grant
    Filed: August 25, 2008
    Date of Patent: December 30, 2014
    Assignee: Sysmex Corporation
    Inventors: Hideki Ishihara, Tomoko Matsushima, Masaki Shibayama
  • Patent number: 8900881
    Abstract: The present invention relates to a quantitative assay device and a method for the determination of an analyte, based on a test strip, which contains a porous test membrane allowing for capillary flow of the analyte and complexes of the analyte, a porous upstream membrane in fluid connection with the test membrane and a porous downstream membrane in fluid connection with the test membrane, wherein the test membrane contains two bands having deposited on there high and low concentrations of different calibrator agents and a test band capable of reacting with conjugated analyte complexes giving rise to a measurable signal.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: December 2, 2014
    Inventor: Jin Po Lee
  • Patent number: 8883966
    Abstract: The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of SEQ ID NOs: 3, 4 and 5 formulated for the treatment or prevention of cancer in a subject. Furthermore, the present invention provides a method of inducing immune response using such oligopeptides and pharmaceutical agents.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: November 11, 2014
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yasuharu Nishimura, Katsunori Imai, Yusuke Nakamura, Takuya Tsunoda
  • Patent number: 8877509
    Abstract: One embodiment of the present invention provides for a method of determining if a sputum sample contains dysplastic or carcinomic cells by obtaining a sputum sample containing cells. The sputum sample is labeled with TCPP to stain cells suspected to be dysplastic or carcinomic. The labeled sputum sample is excited with an excitation wavelength of light of about 475 nm+/?30 nm and emission at about 560 nm+/?30 nm is detected from cells identified to be macrophages. An imager focuses on the plasma membrane of one or more cells suspected to be dysplastic or carcinomic and emission at about 655 nm+/?30 nm, if present, is detected for TCPP labeled cells of the sputum sample after focusing on the plasma membrane of the cells of the sputum sample. Photon flux for each pixel of a sensor is measured to obtain a value for the imaged cell. The measured value is scored to determine if a cell is cancerous or dysplastic.
    Type: Grant
    Filed: July 19, 2010
    Date of Patent: November 4, 2014
    Assignee: bioAffinity Technologies, Inc.
    Inventors: Constance Dorian, John Cousins, Gordon Bennett
  • Publication number: 20140323352
    Abstract: The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing pancreatic cancer in a subject, a method for identifying whether a subject is in need for a therapy of pancreatic cancer or a method for determining whether a pancreatic cancer therapy is successful. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.
    Type: Application
    Filed: November 29, 2012
    Publication date: October 30, 2014
    Applicant: METANOMICS HEALTH GMBH
    Inventors: Regina Reszka, Beate Kamlage, Holger Kalthoff, Bodo Schniewind, Julia Mayerle, Markus M. Lerch, Christian Pilarsky, Robert Grützmann
  • Patent number: 8865413
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: October 21, 2014
    Assignee: Celera Corporation
    Inventors: Bruno Domon, Ian McCaffery, Vaibhav Narayan, Scott Patterson
  • Patent number: 8865420
    Abstract: The present invention provides an approach for the simultaneous determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of potentiators of cellular activation allows for characterization of such pathways and cell populations.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: October 21, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Omar D. Perez, Garry P. Nolan, Jonathan M. Irish
  • Publication number: 20140273248
    Abstract: Methods using the application of the Ca isotope method for diagnosing and monitoring the progression of cancers that cause bone loss. The methods also can be used for evaluating cancer treatments, such as aromatase inhibitors and other chemotherapeutic agents, for effects on bone density so that treatment can be modified.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Ariel Anbar, Joseph Skulan, Gwyneth Gordon, Rafael Fonseca
  • Patent number: 8834878
    Abstract: A method for the treatment of cancer is provided wherein a cancer recognition (CARE) antigen or CARE antibody is administered to a patient. Administration of the CARE antigen or antibody will induce an immune or promote a response of IgM CARE antibodies which will bind to CARE antigen bound to cancer cells, inducing an immune response to destroy the cancer cells. Subsequent to said treatment, ELISA assays may be used to detect levels of said CARE antigen to monitor the efficacy of the treatment, and to govern the further administration of CARE antigens.
    Type: Grant
    Filed: June 6, 2007
    Date of Patent: September 16, 2014
    Inventor: Jerry T. Thornthwaite
  • Patent number: 8828671
    Abstract: Whole cell, simultaneous target and drug-target assay using differentially labeled antibodies and flow cytometry. First antibody binds to total target and second antibody binds to the drug binding site of the target, thus drug binding will competitively inhibit the second antibody allowing for a competitive inhibition assay of drug-target binding. The assay allows for whole cell analysis and even analysis of mixed populations of cells, yet provides detailed kinetic assessment of drug activity.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: September 9, 2014
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Norman B. Purvis, Gregory T. Stelzer
  • Patent number: 8821880
    Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to polypeptide antagonists of PLVAP proteins, including humanized and chimeric antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising such polypeptide antagonists.
    Type: Grant
    Filed: September 9, 2009
    Date of Patent: September 2, 2014
    Assignee: China Synthetic Rubber Corporation
    Inventors: Kuo-Jang Kao, Andrew T. Huang
  • Patent number: 8815527
    Abstract: The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: August 26, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Omar D. Perez, Garry P. Nolan
  • Patent number: 8815092
    Abstract: A microfiltration apparatus and method for separating cells, such as circulating tumor cells, from a sample using a microfiltration device having a top porous membrane and a bottom porous membrane. The porous membranes are formed from parylene and assembled using microfabrication techniques. The porous membranes are arranged so that the pores in the top membrane are offset from the pores in the bottom membrane.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: August 26, 2014
    Assignees: California Institute of Technology, University of Southern California
    Inventors: Siyang Zheng, Richard Cote, Henry Lin, Bo Lu, Yu-Chong Tai
  • Patent number: 8785202
    Abstract: The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a colloidal metal, derivatized PEG (polyethylene glycol) and an agent. The invention also comprises methods and compositions for making such colloidal metal compositions and for treatment of cancer.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: July 22, 2014
    Assignee: CytImmune Sciences, Inc.
    Inventors: Lawrence Tamarkin, Giulio F. Paciotti